Zoetis (NYSE:ZTS) has tumbled 2% during the past week and has dropped 1.32% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 0.83%. Zoetis (NYSE:ZTS) has underperformed the index by 2.22% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Zoetis (NYSE:ZTS): The stock opened at $47.21 on Friday but the bulls could not build on the opening and the stock topped out at $47.26 for the day. The stock traded down to $46.44 during the day, due to lack of any buying support eventually closed down at $46.44 with a loss of -1.74% for the day. The stock had closed at $47.26 on the previous day. The total traded volume was 4,009,953 shares.
The company shares have dropped -7.53% from its 1 Year high price. On Jun 25, 2015, the shares registered one year high at $55.38 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $47.25 and the 200 Day Moving Average price is recorded at $45.08.
Many analysts have stated their opinion on the company shares. Major Brokerage house, Jefferies maintains its ratings on Zoetis (NYSE:ZTS). In the latest research report, Jefferies raises the target price from $57 per share to $58 per share. According to the latest information available, the shares are now rated Buy by the analysts at the agency. The rating by the firm was issued on June 14, 2016. Currently the company Insiders own 0.05% of Zoetis shares according to the proxy statements. Institutional Investors own 93.74% of Zoetis shares.
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses, and five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.